$700 Million is the total value of Nantahala Capital Management's 96 reported holdings in Q3 2012. The portfolio turnover from Q2 2012 to Q3 2012 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2012 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2012-11-14
About Nantahala Capital Management
Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.
Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.
Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.
Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 45 | Q2 2024 | 27.2% |
| CODEXIS INC | 45 | Q2 2024 | 3.9% |
| PATHWARD FINANCIAL INC | 38 | Q2 2024 | 6.3% |
| GOLDEN ENTMT INC | 35 | Q1 2024 | 2.1% |
| SCIENTIFIC GAMES CORP | 34 | Q3 2022 | 5.3% |
| DOVER MOTORSPORTS INC | 34 | Q3 2021 | 0.5% |
| QAD INC | 32 | Q3 2021 | 2.6% |
| SCIENTIFIC GAMES CORP | 31 | Q4 2021 | 7.7% |
| UNIQURE NV | 31 | Q2 2024 | 4.7% |
| DOLBY LABORATORIES INC | 31 | Q4 2020 | 5.6% |
View Nantahala Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AYTU BIOPHARMA, INC | June 18, 2024 | 1,086,812 | 18.2% |
| Rezolute, Inc. | March 11, 2024 | 4,118,164 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2024 | 2,499,781 | 9.9% |
| Aptose Biosciences Inc. | February 14, 2024 | 120,132 | 1.5% |
| Assertio Holdings, Inc. | February 14, 2024 | 7,619,440 | 8.0% |
| Avalo Therapeutics, Inc. | February 14, 2024 | 42,100 | 4.9% |
| Bioventus Inc. | February 14, 2024 | 5,977,471 | 9.5% |
| Cellectar Biosciences, Inc. | February 14, 2024 | 3,229,903 | 9.9% |
| Cidara Therapeutics, Inc. | February 14, 2024 | 1,546,745 | 1.7% |
| CODEXIS, INC. | February 14, 2024 | 4,592,903 | 6.6% |
View Nantahala Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-11-06 |
| SC 13G/A | 2024-11-05 |
| SC 13D/A | 2024-10-01 |
| SC 13D | 2024-09-24 |
| SC 13D | 2024-09-20 |
| N-PX | 2024-08-30 |
| SC 13G/A | 2024-08-30 |
| 13F-HR/A | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-07-03 |
View Nantahala Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.